EC approves Celgene’s Revlimid to treat myelodysplastic syndromes
While other remedial options could not yield desired result, treatment with Revlimid indicated improvements in patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS) with an isolated chromosomal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.